The China cardiovasvular devices market was valued at USD 2837.61  million in 2018, and it is expected to reach USD 4468.02 million by 2024, with an anticipated CAGR of 7.86% during the forecast period, 2019-2024.

The increasing incidence of cardiovascular diseases and the growing geriatric population are the most significant factors driving the growth of the market.

According to a report by the United Nation Economic and Social Commission for Asia and the Pacific (ESCAP), the geriatric population in the Asia-Pacific region was around 617.1 million in 2015, accounting for more than half of the world’s total elderly population. By 2050, Asia-Pacific is estimated to account for almost two-third of the world’s geriatric population. Furthermore, China’s population is aging at a faster rate than almost all other countries of the Asia-Pacific region, which is in part due to the long run of China’s one-child policy and dramatic increase in healthcare facilities. According to the government estimates, the geriatric population may peak at more than 450 million geriatric citizens, by 2050.

The aging process is commonly associated with increased vascular rigidity and decreased vascular compliance. Elderly patients have a high risk of developing cardiovascular disorders, such as peripheral arterial disease (PAD), aortic disease, and venous thromboembolism (VTE). This is primarily due to age-related alterations in vascular structure and rigidity, further compounded by longer exposure to cardiovascular disease (CVD) risk factors. Furthermore, other factors, such as the rapid technological advances, increasing awareness of the population, and high preference of minimally-invasive procedures, are also supplementing the market growth.